Key TakeawaysMenopause hormone therapy appears to boost the effectiveness of tirzepatide (Zepbound)Women lost more weight with the combo, and more women lost at least 20% of body weightThe findings reflect earlier results with semaglutide (Wegovy).MONDAY, July 14, 2025 (HealthDay News) Good news for women of a certain age: Hormone replacement therapy for menopause appears to boost the effectiveness of GLP-1 weight loss drugs like Wegovy and Zepbound, a new study says.Women using tirzepatide (Zepbound) lost more weight if they also were taking hormone therapy 17% of body weight lost versus 14% after a median 18 months, researchers reported Saturday at the Endocrine Societys annual meeting in San Francisco.Further, more women taking Zepbound and hormone therapy achieved at least 20% total body weight loss, with 45% meeting this goal compared to 18% of those not on hormone therapy.These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women, presenting investigator Dr
By revealing how EMFs spatiotemporally coordinate these axes [Figure 1], we redefine a new therapeutic paradigm: exploiting electromagnetic bioeffects to simultaneously disrupt oncogenic circuits (e.g., Ca 2+ -driven stemness, EMF-mediated mechanisms in cancer pathobiology Additionally, sex hormones (particularly androgens) drive PCa progression by activating oncogenic signaling pathways like AR-dependent transcription
Both are administered under local anesthesia
Participants were randomized 2:1:1:1:1:2:2 to receive placebo or retatrutide at 1 mg, 4 mg (starting at 2 mg), 4 mg (starting at 4 mg), 8 mg (starting at 2 mg), 8 mg (starting at 4 mg), or 12 mg (starting at 2 mg) administered subcutaneously once weekly for 48 weeks
Both the injections and pills have similar side effects, including nausea, constipation, vomiting, gallbladder disease, and other gastrointestinal issues
Results from a phase 3 trial of semaglutide in patients with fatty liver disease (medically known as metabolic dysfunction-associated steatohepatitis or MASH) found the drug could halt and even reverse the condition, which affects one in five UK adults
